Format

Send to

Choose Destination
PLoS One. 2019 Apr 10;14(4):e0215340. doi: 10.1371/journal.pone.0215340. eCollection 2019.

Identification of ChIP-seq and RIME grade antibodies for Estrogen Receptor alpha.

Author information

1
Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge, United Kingdom.

Abstract

Estrogen Receptor alpha (ERα) plays a major role in most breast cancers, and it is the target of endocrine therapies used in the clinic as standard of care for women with breast cancer expressing this receptor. The two methods ChIP-seq (chromatin immunoprecipitation coupled with deep sequencing) and RIME (Rapid Immunoprecipitation of Endogenous Proteins) have greatly improved our understanding of ERα function during breast cancer progression and in response to anti-estrogens. A critical component of both ChIP-seq and RIME protocols is the antibody that is used against the bait protein. To date, most of the ChIP-seq and RIME experiments for the study of ERα have been performed using the sc-543 antibody from Santa Cruz Biotechnology. However, this antibody has been discontinued, thereby severely impacting the study of ERα in normal physiology as well as diseases such as breast cancer and ovarian cancer. Here, we compare the sc-543 antibody with other commercially available antibodies, and we show that 06-935 (EMD Millipore) and ab3575 (Abcam) antibodies can successfully replace the sc-543 antibody for ChIP-seq and RIME experiments.

Conflict of interest statement

Jason Carroll is founder and CSO of Azeria Therapeutics. None of the work in this manuscript is related to the work in Azeria Therapeutics. The authors declare no additional competing interests and the declared funding does not alter our adherence to PLOS ONE policies on sharing data and materials.

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center